Incannex achieves database lock for RePOSA Phase 2 trial of IHL-42X; top-line results expected July 2025

Incannex Healthcare Inc.

Database lock achieved June 16, 2025, on schedule; final statistical analysis begins.
Top-line results from Phase 2 trial of IHL-42X for obstructive sleep apnoea expected July 2025.
IHL-42X is a first-in-class oral therapy for OSA; no approved oral pharmacological treatment exists.
Trial evaluates IHL-42X in moderate to severe OSA patients unable/unwilling to use CPAP.
Over 900 million people affected by OSA worldwide; IHL-42X aims to address underserved patient population.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.